Oncology Agents for Cancer Therapy: A Review

Abstract

The introduction of novel agents for the management of advanced prostate cancer has significantly expanded treatment options, particularly benefiting men with metastatic castration-resistant prostate cancer (mCRPC). However, there are still gaps in understanding optimal patient selection, effective sequential use of treatments, and the development of resistance patterns.
Certainly, reviewing current systemic therapies and recent advances in drug development for metastatic castration-resistant prostate cancer (mCRPC), as well as discussing strategies to aid in patient selection and optimal sequencing, is crucial for improving patient outcomes and treatment efficacy. This involves analyzing the latest clinical data, understanding the mechanisms of action of new therapies, and considering factors such as tumor biology, previous treatments, and patient preferences to tailor treatment strategies for each individual. Selective kinase inhibitors have indeed emerged as a significant class of anticancer agents, showing promising clinical efficacy and generally favorable toxicity profiles in various disease settings. They have particularly shown potential in cases where conventional treatments have offered only limited benefit. This underscores their importance in expanding treatment options and improving outcomes for patients across different cancer types.
Keywords: mCRPC, NSCLC